Release Date: 23-Aug-2023
The mounting success of monoclonal antibodies in the last few years combined with targeted drug delivery has opened another window of opportunity andndash; the development of antibody-drug conjugates. Globally more than 15 antibody-drug conjugates have received approval, with the FDA having approved 13 of these. The global antibody-drug conjugate market had a market value of over US$ 8 Billion in 2022, and around US$ 5 Billion in the first half of 2023. A major portion of these values were generated by the antibody-drug conjugates indicated for the treatment of breast cancers, which include Kadcyla and Enhertu, both of which are blockbuster drugs.
Download Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report
https://www.kuickresearch.com/report-cancer-antibody-drug-conjugate-market
In comparison to antibodies, antibody-drug conjugates offer opportunity for a more targeted treatment of different diseases, which has been a major factor driving their development. It is estimated that over 10 new antibody-drug conjugates are in phase III of clinical trials, and some like Trastuzumab duocarmazine are currently under regulatory review. Therefore, approvals of these drugs are anticipated to take the overall sales value of this drug class to the next level in the coming years.